Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine in Treatment-naïve Indian Subjects With HIV-1
NCT03563742Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Sep 2018; status: terminated.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03563742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563742.